Ig κ light chain Inhibitors
Ig κ light chain inhibitors belong to a distinctive chemical class that focuses on targeting the immunoglobulin kappa (Ig κ) light chains. These light chains are integral components of antibodies, which play a crucial role in the immune system's recognition and response to foreign substances, such as pathogens. Ig κ light chain inhibitors are designed to modulate the function of these light chains through specific interactions with their molecular structure. By binding to Ig κ light chains, these inhibitors can influence various immune-related processes.
Their mechanism of action is centered around interfering with the normal binding and recognition functions of Ig κ light chains. This unique class of compounds demonstrates an intricate understanding of the underlying molecular interactions within the immune system. Their development and study contribute to the broader exploration of immune responses and protein-protein interactions.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $49.00 $367.00 $2030.00 | 18 | |
Lenalidomide inhibits Ig κ light chain production by modulating the immune system and affecting cytokines. It also induces apoptosis of Ig κ-producing cells. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib inhibits Ig κ light chain production by targeting the proteasome, leading to the degradation of misfolded proteins and blocking signaling pathways involved in cell survival. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $40.00 | ||
Carfilzomib, a proteasome inhibitor, disrupts Ig κ light chain synthesis by blocking protein degradation processes in cells, thus promoting apoptosis and reducing proliferation. | ||||||
Pomalidomide | 19171-19-8 | sc-364593 sc-364593A sc-364593B sc-364593C sc-364593D sc-364593E | 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $98.00 $140.00 $306.00 $459.00 $1224.00 $1958.00 | 1 | |
Pomalidomide modulates the immune system and inhibits Ig κ light chain production by affecting cytokines. It also has immunomodulatory and anti-angiogenic effects, contributing to its activity. | ||||||
Masitinib | 790299-79-5 | sc-211777 | 10 mg | $180.00 | ||
Marizomib inhibits Ig κ light chain production by targeting the proteasome, disrupting protein degradation and leading to apoptosis of Ig κ-producing cells. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Ixazomib, a proteasome inhibitor, disrupts Ig κ light chain synthesis by inhibiting protein degradation, inducing apoptosis, and affecting cellular pathways involved in cell survival. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $280.00 | 1 | |
MLN4924 inhibits Ig κ light chain production by targeting the NEDD8-activating enzyme, resulting in the disruption of protein homeostasis, cell cycle arrest, and apoptosis. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
Oprozomib is a proteasome inhibitor that disrupts Ig κ light chain synthesis by preventing protein degradation, leading to the accumulation of misfolded proteins and cell death. | ||||||
Delanzomib, free base | 847499-27-8 | sc-396774 sc-396774A | 5 mg 10 mg | $160.00 $300.00 | ||
CEP-18770, a proteasome inhibitor, disrupts Ig κ light chain synthesis by preventing protein degradation. This leads to the buildup of misfolded proteins and triggers apoptosis in the cells. | ||||||